Azilect and Zelapar are new options on the horizon for Parkinson's

July 2006

Azilect and Zelapar are new options on the horizon for Parkinson's.

Azilect (rasagiline) is an MAO-B inhibitor similar to selegiline. It works by blocking the breakdown of dopamine.

Azilect can be used as initial therapy...to improve symptoms in patients with early Parkinson's. It can also be added to levodopa...to prolong its effects in patients with more advanced Parkinson's.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

New guidelines clarify how to reduce the risk of ischemic stroke
Osteoporosis increased risk of death due to stroke with Evista (raloxifene)
Contraceptives Linessa is a new triphasic oral contraceptive in Canada
Vaccines Researchers are using large doses of chickenpox vaccine to prevent shingles
Vaccines new Gardasil vaccine to prevent cervical cancer and genital warts
Gastroenterology probiotics for "digestive health"
Heart Disease new brand of sildenafil called Revatio
Women's Health ACE inhibitors during the first trimester MIGHT increase the risk of birth defects
Women's Health codeine can be toxic to breastfed infants
Dermatology new ORAL "sunscreens" such as SunPill and Heliocare
Azilect and Zelapar are new options on the horizon for Parkinson's
questioning the benefits of taking daily multivitamin and mineral supplements
alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)
Hematology & Oncology new oral cancer drug in Canada called Sutent
Acetaminophen Consumers still aren't getting the message about the danger of taking too much acetaminophen
many drugs can cause sweating
Practice two new investigational drugs for type 2 diabetes, Januvia and Galvus

Azilect and Zelapar are new options on the horizon for Parkinson's

Practical advice for a better career, with unlimited access to CE

Table of Contents